Breaking News Instant updates and real-time market news.

ARDM

Aradigm

$5.24

0.04 (0.77%)

07:22
12/01/16
12/01
07:22
12/01/16
07:22

Aradigm says Pulmaquin 'safe,' 'well tolerated' in ORBIT-3, ORBIT-4 trials

Aradigm announced top-line results from its two Phase 3 clinical trials evaluating the safety and efficacy of Pulmaquin, the company's investigational proprietary formulation of once daily ciprofloxacin for inhalation, in patients with non-cystic fibrosis bronchiectasis with chronic lung infections with Pseudomonas aeruginosa. The ORBIT-3 and ORBIT-4 pivotal trials were identical in design except for a pharmacokinetics sub-study that was conducted in one of the trials. The primary endpoint in both ORBIT-3 and ORBIT-4 was an increase in the median time to first mild, moderate or severe pulmonary exacerbation. The key secondary efficacy endpoint in both trials was the frequency of PE's over the 48-week double-blind treatment period. In ORBIT-4 the median time to first mild, moderate or severe PE was 230 days in the Pulmaquin treatment group as compared to 163 days in the placebo group. This increase in the median time to first PE was statistically significant using non-stratified log-rank analysis. In the key secondary efficacy endpoint, there was a 37% reduction in the frequency of PE's over the 48-week treatment period in the Pulmaquin treatment group as compared to the placebo group. This result was statistically significant with a Hazard Ratio of Pulmaquin/placebo of 0.63 using non-stratified binomial regression. In ORBIT-3 the median time to first mild, moderate or severe PE was 221 days in the Pulmaquin treatment group as compared to 136 days in the placebo group. This increase in the median time to first PE was similar to ORBIT-4 but was not statistically significant using non-stratified log-rank analysis. In the key secondary efficacy endpoint, there was a 13% reduction in the frequency of PE's over the 48-week treatment period in the Pulmaquin treatment group as compared to the placebo group. This result was not statistically significant with a Hazard Ratio of Pulmaquin/placebo of 0.87 using non-stratified binomial regression. The analyses of combined data from both studies resulted in a statistically significant reduction in the number of PE's over the 48-week double-blind period, representing a 27% reduction in PE's over the period. When the additional analyses of combined data from both studies were conducted taking into account only PE's that were moderate or severe the median time to first PE in the Pulmaquin group was 302 days vs. placebo 198 days. There was also a statistically significant reduction in the number of moderate and severe PE's over the 48-week double-blind period using non-stratified analysis, representing a 33% reduction in PE's over the period. In each study, the treatment groups were stratified for gender, pre-trial frequency of exacerbations and smoking status. The Statistical Analysis Plan for the studies called for stratified analyses; however, since some strata were found to have no or very few subjects, both non-stratified and stratified analyses were conducted. The company believes that due to the limited number of subjects in some strata the non-stratified analyses are more appropriate as strata that are too small can produce highly unstable estimated treatment effects with potential outliers. Using the stratified analyses, the median time to first PE in ORBIT-3 was Pulmaquin: 221 days; placebo: 136 days; p=0.7681 and for ORBIT-4 was Pulmaquin: 230 days; placebo: 163 days; p=0.0885. Both studies demonstrated a statistically significant reduction in P. aeruginosa density at Day 28, the end of the first on-treatment period. For each study, the magnitude of this antibiotic effect remained persistent throughout all on-treatment periods. Pulmaquin was safe and well tolerated in both studies. There were no differences in the changes of lung function or symptoms of airway irritation between the Pulmaquin and placebo groups in the two studies. Overall, the incidence of all treatment emergent adverse events was similar between the Pulmaquin and placebo groups in both ORBIT-3 and ORBIT-4. In ORBIT-3 the rates of serious TEAEs were 30.6% with Pulmaquin and 25.3% with placebo while in ORBIT-4 the rates were 17.0% versus 28.6%. For each study, the randomization rate of Pulmaquin treated subjects to placebo was 2 to 1. There were 8 deaths in ORBIT-3 and 6 deaths in ORBIT-4; placebo: 4. None of the deaths was related to Pulmaquin or placebo. The most frequently observed treatment related TEAEs were of respiratory/thoracic/mediastinal nature and were reported in ORBIT-3 by 25.7% of subjects with Pulmaquin and in 21.1% of subjects with placebo, while the rates in ORBIT-4 were 16.5% with Pulmaquin versus 19.4% with placebo. After the completion of the 48-week double-blind period, both Pulmaquin and placebo treated patients were given the opportunity to receive Pulmaquin in a 28-day open label extension period. 89% of the patients who completed ORBIT-3 and 91% of the patients who completed ORBIT-4 enrolled in the extension period. The company also announced that it has received the final statistical analysis report from the two year inhalation carcinogenicity study in rats with Pulmaquin; there were no differences in the rate of observed tumors between the Pulmaquin and control groups. Aradigm has been granted orphan drug designation for Pulmaquin for non-CF BE in the U.S. In addition, FDA has designated Pulmaquin as a Qualified Infectious Disease Product. The QIDP designation is granted for treatment of non-CF BE patients with chronic lung infections with P. aeruginosa and made Pulmaquin eligible for Fast Track designation which was granted by the FDA in September 2014. Further data from the Phase 3 studies will be presented in future publications and medical meetings.

TODAY'S FREE FLY STORIES

ICPT

Intercept

$61.59

-12.11 (-16.43%)

07:47
09/25/17
09/25
07:47
09/25/17
07:47
Recommendations
Intercept analyst commentary  »

Intercept selloff…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BOX

Box

$18.17

0.7 (4.01%)

07:47
09/25/17
09/25
07:47
09/25/17
07:47
Upgrade
Box rating change  »

Box upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Oct

SCM

Stellus Capital

$13.63

-0.02 (-0.15%)

07:46
09/25/17
09/25
07:46
09/25/17
07:46
Initiation
Stellus Capital initiated  »

Stellus Capital initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KKR

KKR

$19.73

0.42 (2.18%)

07:46
09/25/17
09/25
07:46
09/25/17
07:46
Periodicals
KKR raises offer for Australia's Pepper Group to $543M, Reuters says »

KKR has raised its bid…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VSR

Versar

$0.48

0.033 (7.33%)

07:44
09/25/17
09/25
07:44
09/25/17
07:44
Hot Stocks
Breaking Hot Stocks news story on Versar »

Versar trading halted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TXN

Texas Instruments

$88.27

2.22 (2.58%)

07:44
09/25/17
09/25
07:44
09/25/17
07:44
Recommendations
Texas Instruments analyst commentary  »

Texas Instruments…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PSTG

Pure Storage

$15.64

0.62 (4.13%)

07:42
09/25/17
09/25
07:42
09/25/17
07:42
Recommendations
Pure Storage analyst commentary  »

Pure Storage price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 11

    Dec

PGR

Progressive

$47.98

0.3 (0.63%)

07:41
09/25/17
09/25
07:41
09/25/17
07:41
Recommendations
Progressive analyst commentary  »

Progressive outlook has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPC

Genuine Parts

$87.98

1.63 (1.89%)

07:41
09/25/17
09/25
07:41
09/25/17
07:41
Conference/Events
Genuine Parts to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 19

    Oct

  • 30

    Oct

TFX

Teleflex

$241.77

4.71 (1.99%)

07:41
09/25/17
09/25
07:41
09/25/17
07:41
Recommendations
Teleflex analyst commentary  »

Teleflex price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Dec

BAS

Basic Energy

$17.24

-0.34 (-1.93%)

07:41
09/25/17
09/25
07:41
09/25/17
07:41
Recommendations
Basic Energy analyst commentary  »

Basic Energy price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 27

    Sep

  • 16

    May

EONGY

E.ON AG

$11.19

0.2 (1.82%)

07:38
09/25/17
09/25
07:38
09/25/17
07:38
Periodicals
E.ON CFO defends plan to sell Uniper stake to Fortum, Reuters reports »

E.ON CFO Marc Spieker…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGN

Allergan

$204.65

1.99 (0.98%)

07:36
09/25/17
09/25
07:36
09/25/17
07:36
Hot Stocks
Allergan announces resignation of CFO Tessa Hilado »

Allergan announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

WBC

Wabco

$150.14

0.95 (0.64%)

07:36
09/25/17
09/25
07:36
09/25/17
07:36
Initiation
Wabco initiated  »

Wabco initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

FNV

Franco-Nevada

$79.32

0.4 (0.51%)

07:35
09/25/17
09/25
07:35
09/25/17
07:35
Downgrade
Franco-Nevada rating change  »

Franco-Nevada downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PTN

Palatin

$0.66

0.06 (10.00%)

07:35
09/25/17
09/25
07:35
09/25/17
07:35
Earnings
Palatin reports Q4 EPS 7c, may not compare to consensus (2c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

AAPL

Apple

$151.89

-1.5 (-0.98%)

, GE

General Electric

$24.87

0.12 (0.48%)

07:35
09/25/17
09/25
07:35
09/25/17
07:35
Options
Unusual call flow in option market yesterday »

Notable call activity was…

AAPL

Apple

$151.89

-1.5 (-0.98%)

GE

General Electric

$24.87

0.12 (0.48%)

ORCL

Oracle

$48.16

0.19 (0.40%)

M

Macy's

$21.53

0.37 (1.75%)

COP

ConocoPhillips

$49.08

0.39 (0.80%)

FCAU

Fiat Chrysler

$17.95

0.58 (3.34%)

WETF

WisdomTree

$9.25

0.23 (2.55%)

KBH

KB Home

$20.88

0.1 (0.48%)

MDR

McDermott

$7.01

0.1 (1.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 27

    Sep

  • 28

    Sep

  • 02

    Oct

  • 22

    Oct

ONCE

Spark Therapeutics

$85.15

-1.95 (-2.24%)

07:33
09/25/17
09/25
07:33
09/25/17
07:33
Hot Stocks
Spark Therapeutics appoints Dr. Federico Mingozzi as Chief Scientific Officer »

Spark Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 12

    Oct

  • 12

    Jan

AGN

Allergan

$204.65

1.99 (0.98%)

07:32
09/25/17
09/25
07:32
09/25/17
07:32
Hot Stocks
Allergan announces new $2B share repurchase plan, affirms guidance »

Allergan announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

ECA

Encana

$11.25

-0.05 (-0.44%)

07:31
09/25/17
09/25
07:31
09/25/17
07:31
Recommendations
Encana analyst commentary  »

Encana price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGN

Allergan

$204.65

1.99 (0.98%)

07:30
09/25/17
09/25
07:30
09/25/17
07:30
Hot Stocks
Breaking Hot Stocks news story on Allergan »

Allergan announces new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

EXAS

Exact Sciences

$45.96

0.96 (2.13%)

, ROK

Rockwell Automation

$177.55

0.22 (0.12%)

07:30
09/25/17
09/25
07:30
09/25/17
07:30
Options
Unusual put flow in option market yesterday »

Notable put activity was…

EXAS

Exact Sciences

$45.96

0.96 (2.13%)

ROK

Rockwell Automation

$177.55

0.22 (0.12%)

DVA

DaVita

$57.49

-3.77 (-6.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Nov

NTDOY

Nintendo

$45.62

-0.98 (-2.10%)

, GOOG

Alphabet

$928.53

-3.92 (-0.42%)

07:29
09/25/17
09/25
07:29
09/25/17
07:29
Periodicals
Nintendo adds two-factor authentication for accounts, the Verge says »

Nintendo (NTDOY) users…

NTDOY

Nintendo

$45.62

-0.98 (-2.10%)

GOOG

Alphabet

$928.53

-3.92 (-0.42%)

GOOGL

Alphabet Class A

$943.26

-4.29 (-0.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 22

    Oct

  • 29

    Nov

EGO

Eldorado Gold

$2.26

0.02 (0.89%)

07:29
09/25/17
09/25
07:29
09/25/17
07:29
Upgrade
Eldorado Gold rating change  »

Eldorado Gold upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

APRN

Blue Apron

$5.19

-0.04 (-0.76%)

07:28
09/25/17
09/25
07:28
09/25/17
07:28
Initiation
Blue Apron initiated  »

Blue Apron initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.